D.E. Shaw & Co
EDIT icon

D.E. Shaw & Co’s Editas Medicine EDIT Stock Holding History

D.E. Shaw & Co’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-40,000
Closed -$473K – 5267
2022
Q2 		$473K Sell
40,000
-184,600
-82% -$2.47M ﹤0.01% 4119
2022
Q1 		$4.27M Buy
224,600
+105,400
+88% +$1.96M ﹤0.01% 2503
2021
Q4 		$3.17M Buy
119,200
+39,200
+49% +$1.35M ﹤0.01% 2900
2021
Q3 		$3.29M Sell
80,000
-70,000
-47% -$3.84M ﹤0.01% 2539
2021
Q2 		$8.5M Buy
150,000
+90,000
+150% +$3.32M 0.01% 1635
2021
Q1 		$2.52M Buy
+60,000
New +$3.42M ﹤0.01% 2393

Other funds holding EDIT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

D.E. Shaw & Co's EDIT Position: Q1 2026 in Review

D.E. Shaw & Co increased its Editas Medicine (EDIT) stake by 75% in Q1 2026, buying an estimated $1.77M and bringing the position to 1,943,893 shares worth $4.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2212.

D.E. Shaw & Co first reported a position in EDIT in Q4 2016 and has held it in 38 quarters since. The position peaked at $98.8M in Q4 2020. 207 funds tracked by Wall St. Rank hold EDIT as of Q1 2026.

  • D.E. Shaw & Co held 1,943,893 shares of Editas Medicine worth $4.8M as of Q1 2026.
  • D.E. Shaw & Co bought 834,303 Editas Medicine shares in Q1 2026, an estimated $1.77M.
  • Editas Medicine made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #2212 holding.
  • D.E. Shaw & Co first reported a position in Editas Medicine in Q4 2016 and has held it in 38 quarters since.
  • D.E. Shaw & Co's Editas Medicine position peaked at $98.8M in Q4 2020.
  • 207 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.